For research use only
| Cat No. | ABC-X0353C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Lymphocytes |
| Species | Human |
| Host Cell | BAF3 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Storage | Liquid Nitrogen |
Human ERBB2 (D769Y) BAF3 Cell Line, ERBB2, BAF3, Overexpression Stable Cell Lines, Transfected Stable Cell Lines
Human ERBB2 (D769Y) BAF3 Overexpression Cell Line is a genetically engineered model developed from murine BAF3 pro-B cells based on customers’ requirement. This cell line stably expresses the human ERBB2 (HER2) gene with the D769Y mutation introduced through lentiviral transduction. Gene expression is validated by qRT-PCR and the cells are maintained under low passage (<P20). Target ERBB2 (HER2) encodes a receptor tyrosine kinase overexpressed or mutated in breast, gastric, and lung cancers. The D769Y mutation is located in the kinase domain and enhances constitutive signaling, promoting cell proliferation and therapeutic resistance. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers’ research needs.
| Species | Human |
| Cat.No | ABC-X0353C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocytes |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO2 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | BAF3 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
This cell model expresses the oncogenic D769Y mutant of ERBB2 (HER2), a variant associated with constitutive kinase activation in breast and gastric cancers. It enables functional studies of HER2 signaling, drug screening for HER2-targeted therapies, and analysis of downstream pathways like PI3K-AKT and MAPK. The cell line is widely used to evaluate therapeutic sensitivity and resistance mechanisms involving ERBB2 mutations.